SAN DIEGO, CA–(Marketwired – April 27, 2015) – NuVasive, Inc. (NASDAQ: NUVA) (“NuVasive or the “Company”), a leading medical device company focused on transforming spine surgery with
minimally disruptive, procedurally integrated solutions, today announced its participation at the 83rd American Association of Neurological Surgeons (“AANS”) Annual Meeting, held May 2-6, 2015, at the Walter E. Washington Convention Center in Washington, D.C.
The Company’s presence will be highlighted by the launch of a new global spine alignment surgical platform that builds on NuVasive’s consistent track-record of introducing innovative procedurally integrated products that revolutionize the spine industry and improve patient outcomes.
Surgical Platform Launch and Live Demonstrations (Booth #1031)
NuVasive’s new surgical platform will officially launch at the Company’s exhibition booth (#1031), beginning May 4, 2015, at 9:00 a.m. ET.
During NuVasive’s participation at AANS, booth visitors will have the opportunity on May 4, 2015 from 3:30 p.m. to 4:00 p.m. ET to meet Bill Walton, National Basketball Hall of Fame legend and spokesman for The Better Way Back®, NuVasive’s patient support and education foundation. Surgeons will also have an opportunity to participate in hands-on demonstrations of the surgical platform in the Company’s exhibition booth throughout the three-day meeting.
Additional opportunities for participation include a “Lunch and Learn” seminar hosted by NuVasive, which takes place Monday, May 4, 2015 from 1:15 p.m. to 2:00 p.m. ET in room 144 AB at the Walter E. Washington Convention Center.
For more information, view the online AANS program (link) or visit the AANS website (link).
About NuVasive
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the third largest player in the $9.0 billion global spine market. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company’s principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive cautions you that statements included in this news release or made during the 2015 AANS Annual Meeting that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of its network of sales representatives, and the other risks and uncertainties more fully described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.